FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368405605> ?p ?o ?g. }

• W4368405605 endingPage "4699" @default.
• W4368405605 startingPage "4688" @default.
• W4368405605 abstract "Pancreatic cancer has an annual incidence of 2/10,000 in Canada, with a one-year mortality rate greater than 80%. In the absence of a cost-effectiveness analysis in Canada, this study’s objective was to assess the cost-effectiveness of olaparib versus a placebo in adult patients with deleterious or suspected deleterious BRCA metastatic pancreatic adenocarcinoma, who did not show any progression for at least 16 weeks with first-line platinum-based chemotherapy. A partitioned survival model with a 5-year time horizon was adopted to estimate the costs and effectiveness. All of the costs were extracted from the public payer’s available resources, effectiveness data were obtained from the POLO trial, and Canadian studies were used for utility inputs. Probabilistic sensitivity analyses and scenario analyses were performed. The total costs of olaparib and the placebo over five years were CAD 179,477 and CAD 68,569, with overall quality-adjusted life-years (QALYs) of 1.70 and 1.36, respectively. The incremental cost-effectiveness ratio (ICER) of the olaparib group compared with the placebo was CAD 329,517 per QALY. With a commonly cited willingness to pay (WTP) threshold of CAD 50,000 per QALY, the drug does not achieve acceptable cost-effectiveness mainly due to the high price of the medication and insufficient impact on the overall survival of patients with metastatic pancreatic cancer." @default.
• W4368405605 created "2023-05-05" @default.
• W4368405605 creator A5031472854 @default.
• W4368405605 creator A5041950116 @default.
• W4368405605 creator A5045823954 @default.
• W4368405605 creator A5082899051 @default.
• W4368405605 creator A5086718931 @default.
• W4368405605 date "2023-05-02" @default.
• W4368405605 modified "2023-09-28" @default.
• W4368405605 title "Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective" @default.
• W4368405605 cites W1541614505 @default.
• W4368405605 cites W1785779992 @default.
• W4368405605 cites W1992428774 @default.
• W4368405605 cites W2005295931 @default.
• W4368405605 cites W2019607817 @default.
• W4368405605 cites W2097642908 @default.
• W4368405605 cites W2134291881 @default.
• W4368405605 cites W2151253787 @default.
• W4368405605 cites W2165480504 @default.
• W4368405605 cites W2535056227 @default.
• W4368405605 cites W2593526662 @default.
• W4368405605 cites W2782066272 @default.
• W4368405605 cites W2782876837 @default.
• W4368405605 cites W2795392586 @default.
• W4368405605 cites W2805464686 @default.
• W4368405605 cites W2936922671 @default.
• W4368405605 cites W2976441305 @default.
• W4368405605 cites W2988728533 @default.
• W4368405605 cites W3017182554 @default.
• W4368405605 cites W3024200867 @default.
• W4368405605 cites W3043343659 @default.
• W4368405605 cites W3043777046 @default.
• W4368405605 cites W3047482470 @default.
• W4368405605 cites W3095353870 @default.
• W4368405605 cites W3113156342 @default.
• W4368405605 cites W3136534534 @default.
• W4368405605 cites W3153404280 @default.
• W4368405605 cites W3162861493 @default.
• W4368405605 cites W3205937969 @default.
• W4368405605 cites W4211122150 @default.
• W4368405605 cites W4211208840 @default.
• W4368405605 cites W4214907078 @default.
• W4368405605 cites W4225272251 @default.
• W4368405605 doi "https://doi.org/10.3390/curroncol30050354" @default.
• W4368405605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37232812" @default.
• W4368405605 hasPublicationYear "2023" @default.
• W4368405605 type Work @default.
• W4368405605 citedByCount "0" @default.
• W4368405605 crossrefType "journal-article" @default.
• W4368405605 hasAuthorship W4368405605A5031472854 @default.
• W4368405605 hasAuthorship W4368405605A5041950116 @default.
• W4368405605 hasAuthorship W4368405605A5045823954 @default.
• W4368405605 hasAuthorship W4368405605A5082899051 @default.
• W4368405605 hasAuthorship W4368405605A5086718931 @default.
• W4368405605 hasBestOaLocation W43684056051 @default.
• W4368405605 hasConcept C104317684 @default.
• W4368405605 hasConcept C112930515 @default.
• W4368405605 hasConcept C121608353 @default.
• W4368405605 hasConcept C126322002 @default.
• W4368405605 hasConcept C142724271 @default.
• W4368405605 hasConcept C143998085 @default.
• W4368405605 hasConcept C182979987 @default.
• W4368405605 hasConcept C185592680 @default.
• W4368405605 hasConcept C204787440 @default.
• W4368405605 hasConcept C27081682 @default.
• W4368405605 hasConcept C2779138821 @default.
• W4368405605 hasConcept C2779962180 @default.
• W4368405605 hasConcept C2780194787 @default.
• W4368405605 hasConcept C2780210213 @default.
• W4368405605 hasConcept C3019080777 @default.
• W4368405605 hasConcept C530470458 @default.
• W4368405605 hasConcept C55493867 @default.
• W4368405605 hasConcept C64332521 @default.
• W4368405605 hasConcept C71924100 @default.
• W4368405605 hasConcept C82381507 @default.
• W4368405605 hasConceptScore W4368405605C104317684 @default.
• W4368405605 hasConceptScore W4368405605C112930515 @default.
• W4368405605 hasConceptScore W4368405605C121608353 @default.
• W4368405605 hasConceptScore W4368405605C126322002 @default.
• W4368405605 hasConceptScore W4368405605C142724271 @default.
• W4368405605 hasConceptScore W4368405605C143998085 @default.
• W4368405605 hasConceptScore W4368405605C182979987 @default.
• W4368405605 hasConceptScore W4368405605C185592680 @default.
• W4368405605 hasConceptScore W4368405605C204787440 @default.
• W4368405605 hasConceptScore W4368405605C27081682 @default.
• W4368405605 hasConceptScore W4368405605C2779138821 @default.
• W4368405605 hasConceptScore W4368405605C2779962180 @default.
• W4368405605 hasConceptScore W4368405605C2780194787 @default.
• W4368405605 hasConceptScore W4368405605C2780210213 @default.
• W4368405605 hasConceptScore W4368405605C3019080777 @default.
• W4368405605 hasConceptScore W4368405605C530470458 @default.
• W4368405605 hasConceptScore W4368405605C55493867 @default.
• W4368405605 hasConceptScore W4368405605C64332521 @default.
• W4368405605 hasConceptScore W4368405605C71924100 @default.
• W4368405605 hasConceptScore W4368405605C82381507 @default.
• W4368405605 hasIssue "5" @default.
• W4368405605 hasLocation W43684056051 @default.
• W4368405605 hasLocation W43684056052 @default.

• next